Compare Inovio Pharmaceuticals Inc (INO) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs SpaceX — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while SpaceX trades at $146.22 (market cap $1.76T). The key difference: SpaceX is far larger — about 22406.1× Inovio Pharmaceuticals Inc's market cap, and SpaceX is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SPCX | |
|---|---|---|
Market Cap | $78.55M | $1.76T |
Sector | Health | Technology |
52-Week High | $2.87 | $202.09 |
52-Week Low | $0.66 | $108.27 |
Enterprise Value | $49.56M | $1.70T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
SPCX stock trades at $147.99, up 6.67% today, with a bullish technical signal and strong analyst support. Recent news highlights AI growth and a $1.2 billion stake by Norway's sovereign wealth fund. However, the company shows negative net income margins and high valuation ratios, with revenue growth offset by profitability challenges.
The outlook is mixed: bullish sentiment and AI expansion offer upside, but high valuation and persistent losses pose risks. The consensus price target of $228.52 suggests potential growth, yet investors must weigh innovation against financial sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
